Literature DB >> 2793385

Inefficacy of methylglyoxal bis(guanylhydrazone) (MGBG) in patients with recurrent head and neck squamous cell carcinoma.

C L Arteaga1, G M Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2793385     DOI： 10.1007/bf00170874

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  7 in total

1.  Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck.

Authors:  D J Perry; S M Crain; M D Weltz; J P Wilson; R K Davis; P V Woolley; A A Forastiere; H G Taylor; R B Weiss
Journal:  Cancer Treat Rep       Date:  1983-01

2.  Phase II trial of mitoguazone in patients with advanced head and neck cancer.

Authors:  S Thongprasert; G J Bosl; N L Geller; R E Wittes
Journal:  Cancer Treat Rep       Date:  1984-10

3.  Phase II trials of methylglyoxal-bis (guanylhydrazone).

Authors:  D P Kelsen; A Yagoda; R Warrell; R Chapman; R Whittes; R J Gralla; E Casper; C W Young
Journal:  Am J Clin Oncol       Date:  1982-04       Impact factor: 2.339

4.  Specific inhibition of the enzymic decarboxylation of S-adenosylmethionine by methylglyoxal bis(guanylhydrazone) and related substances.

Authors:  A Corti; C Dave; H G Williams-Ashman; E Mihich; A Schenone
Journal:  Biochem J       Date:  1974-05       Impact factor: 3.857

Review 5.  Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects.

Authors:  R P Warrell; J H Burchenal
Journal:  J Clin Oncol       Date:  1983-01       Impact factor: 44.544

6.  Phase I-II trial of methyl-GAG: a Southwest Oncology Group Pilot Study.

Authors:  W A Knight; R B Livingston; C Fabian; J Costanzi
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

7.  Phase II trial of methylglyoxal bis (guanylhydrazone) (MGBG) in advanced head and neck cancer.

Authors:  A A Forastiere; R B Natale; R R Wheeler
Journal:  Cancer       Date:  1986-12-15       Impact factor: 6.860
  7 in total
  1 in total

1.  Expression of Tumor Suppressor SFRP1 Predicts Biological Behaviors and Prognosis: A Potential Target for Oral Squamous Cell Carcinoma.

Authors:  Chun Chen; Yifei Zhang; Yupeng Liu; Lei Hang; Jun Yang
Journal:  Biomolecules       Date:  2022-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.